Clinical Pharmacology & Therapeutics · 2009 · 766 citations · 5 references
MedicineOncologyPharmacologyBreast OncologyChemotherapyTranslational OncologyBiomarker-guided Therapy SelectionClinical Trial PhasesClinical TrialsClinical Trials In OncologyNeoadjuvant ChemotherapyNeoadjuvant TherapyAdaptive Neoadjuvant TherapyBiomarker-driven Clinical Trial DesignBiomarker-guided Neoadjuvant TherapyNeoadjuvant Clinical TrialsPhase Ii Clinical TrialsPhase Ii Oncology TrialsTherapeutic Response MonitoringTherapeutic Response Prediction
I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. The framework is an adaptive phase II clinical trial design in the neoadjuvant setting for women with locally advanced breast cancer. I-SPY 2 is a collaborative effort among academic investigators, the National Cancer Institute, the US Food and Drug Administration, and the pharmaceutical and biotechnology industries under the auspices of the Foundation for the National Institutes of Health Biomarkers Consortium.
5
Clinical Application of the 70-Gene Profile: The MINDACT Trial
Fátima Cardoso, Laura van’t Veer, Emiel J. Rutgers et al. · Journal of Clinical Oncology · 2008 · 465 citations
Locally Advanced Breast Cancer
Vicente Valero, Aman U. Buzdar, Gabriel N. Hortobágyi · The Oncologist · 1996 · 166 citations · Full text
Medicine, Oncology, Breast Oncology +15
Physicochemically modified silicon as a substrate for protein microarrays
A.J. Nijdam, Mark Ming‐Cheng Cheng, David Geho et al. · Biomaterials · 2006 · 69 citations